CD274 and Autoimmunity: So far, we discussed how the PD-1/PD-L1 axis could be exploited to control β cell autoimmunity and preserve β cell mass in individuals with newly diagnosed T1D (stage 3 T1D) or with high genetic risk to develop disease with or without autoantibodies positivity (stage 0 and stage 1/2 T1D).